<![CDATA[Sanofi ]]>enghttp://www.nasdaqomx.comCopyright (c)2014 NASDAQ OMXhttp://blogs.law.harvard.edu/tech/rssNASDAQ OMX - http://www.nasdaqomx.com/onlineservices@nasdaqomx.com (NASDAQ OMX)onlineservices@nasdaqomx.com (NASDAQ OMX)10<![CDATA[Sanofi ]]>http://www.huginonline.com/France/SANOFI/logo.jpghttp://www.huginonline.com450160<![CDATA[Sanofi: Effect of Genzyme's Multiple Sclerosis Treatment Lemtrada® (alemtuzumab) on Slowing Brain Atrophy and MRI Lesion Activity Maintained Through Four Years]]>Thu, 23 Apr 2015 15:00:00 +0200http://cws.huginonline.com/S/152918/PR/201504/1913575_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201504/1913575_5.htmlhttp://hugin.info/152918/R/1913575/683501.pdf<![CDATA[Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide)]]>Thu, 19 Mar 2015 07:00:00 +0100http://cws.huginonline.com/S/152918/PR/201503/1904474_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201503/1904474_5.htmlhttp://hugin.info/152918/R/1904474/679070.pdf<![CDATA[Sanofi: Shantha will provide up to 37 million doses of Shan5(TM)]]>Tue, 17 Mar 2015 07:00:00 +0100http://cws.huginonline.com/S/152918/PR/201503/1903845_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201503/1903845_5.htmlhttp://hugin.info/152918/R/1903845/679077.pdf<![CDATA[Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine]]>Sun, 15 Mar 2015 15:58:00 +0100http://cws.huginonline.com/S/152918/PR/201503/1903633_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201503/1903633_5.htmlhttp://hugin.info/152918/R/1903633/679085.pdf<![CDATA[Sanofi: Filing of the 2014 U.S. Form 20-F and French "Document de Référence" containing the Annual Financial Report]]>Thu, 12 Mar 2015 13:16:11 +0100http://cws.huginonline.com/S/152918/PR/201503/1902777_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201503/1902777_5.htmlhttp://hugin.info/152918/R/1902777/679092.pdf<![CDATA[Sanofi Appoints Robert Castaigne as Audit Committee Chairman]]>Fri, 6 Mar 2015 16:00:00 +0100http://cws.huginonline.com/S/152918/PR/201503/1900166_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201503/1900166_5.htmlhttp://hugin.info/152918/R/1900166/679099.pdf<![CDATA[Toujeo® Receives Positive Opinion from the European Regulatory Authorities]]>Fri, 27 Feb 2015 13:15:43 +0100http://cws.huginonline.com/S/152918/PR/201502/1897975_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201502/1897975_5.htmlhttp://hugin.info/152918/R/1897975/673928.pdf<![CDATA[Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo®]]>Thu, 26 Feb 2015 02:00:58 +0100http://cws.huginonline.com/S/152918/PR/201502/1897483_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201502/1897483_5.htmlhttp://hugin.info/152918/R/1897483/673570.pdf<![CDATA[Sanofi : Sanofi Appoints Olivier Brandicourt as Chief Executive Officer ]]>Thu, 19 Feb 2015 22:45:00 +0100http://cws.huginonline.com/S/152918/PR/201502/1896027_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201502/1896027_5.htmlhttp://hugin.info/152918/R/1896027/672616.pdf<![CDATA[Sanofi: Sanofi and Lead Pharma to Develop Treatments for Autoimmune Diseases ]]>Wed, 18 Feb 2015 07:00:00 +0100http://cws.huginonline.com/S/152918/PR/201502/1895071_5.htmlSanofi http://cws.huginonline.com/S/152918/PR/201502/1895071_5.htmlhttp://hugin.info/152918/R/1895071/675301.pdf